Latest Articles

Publication Date
A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer - 2 Minute Medicine

A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer 2 Minute Medicine

Published: Oct. 2, 2026, 5:18 a.m.
A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer - 2minutemedicine.com

A long-term gonadotropin-releasing hormone agonist protocol may be associated with increased positive pregnancy outcomes in women with endometriosis undergoing frozen embryo transfer 2minutemedicine.com

Published: Oct. 2, 2026, 5:18 a.m.
[A national questionnaire survey of the current status of diagnosis and treatment of endometriosis in China in 2024].

Objective: To investigate the current status of clinical practice and the implementation of existing guidelines for endometriosis in China, and to provide a reliable basis for relevant continuing medical education …

Published: Sept. 29, 2026, midnight
Thoracic and Umbilical Endometriosis Concurrently Presenting During Secondary Subfertility Evaluation.

Thoracic endometriosis is a rare manifestation of extra pelvic endometriosis and it is often missed because of its variable clinical presentation. A 33-year-old woman undergoing evaluation for secondary subfertility presented …

Published: Sept. 22, 2026, midnight
Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial.

Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …

Published: Sept. 5, 2026, midnight
Endometriosis-associated bone loss: re-evaluating the potential role of systemic inflammation and hypoestrogenic therapies.

Endometriosis is frequently managed with hormonal suppression that can induce hypoestrogenism during a period when many patients are still accruing peak bone mass. This narrative review summarizes current clinical and …

Published: Aug. 19, 2026, midnight
Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review.

In women with uterine adenomyosis, bleeding and pain can have a major impact on quality of life. There is clearly widespread demand for effective long-term medical therapies. The objective of …

Published: Aug. 14, 2026, midnight
Hormonal therapies for endometriosis-associated pain: inflammatory limitations and pharmacological challenges.

Endometriosis is a chronic inflammatory and estrogen-dependent disease in which pain remains the leading cause of impaired quality of life. Hormonal therapies constitute the cornerstone of medical management and include …

Published: Aug. 11, 2026, midnight
When It's Not Just "That Time of the Month": Identifying Thoracic Endometriosis in the Context of Recurrent Pleural Effusion.

Recurrent hemorrhagic pleural effusion presents as a challenge for both the clinician and the patient, with common causes being tuberculosis, malignancy, and collagen vascular diseases. Among uncommon causes of recurrent …

Published: Aug. 4, 2026, midnight
Pulmonary alveolar proteinosis diagnosed during leuprorelin acetate therapy for ovarian endometrioma: a case report.

Pulmonary alveolar proteinosis (PAP) is a rare pulmonary disorder characterized by impaired surfactant clearance due to alveolar macrophage dysfunction. Leuprorelin acetate, a gonadotropin-releasing hormone agonist, is widely used in the …

Published: July 17, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!